Quarterly Consolidated Statement Of Cash Flows

TAIKO PHARMACEUTICAL CO., LTD. - Filing #7270730

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
168,000,000 JPY
282,000,000 JPY
Interest and dividends received
32,000,000 JPY
25,000,000 JPY
Interest paid
-8,000,000 JPY
-8,000,000 JPY
Income taxes paid
-30,000,000 JPY
0 JPY
Net cash provided by (used in) operating activities
362,000,000 JPY
-307,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-157,000,000 JPY
-97,000,000 JPY
Proceeds from sale of property, plant and equipment
JPY
170,000,000 JPY
Proceeds from sale of investment securities
11,000,000 JPY
621,000,000 JPY
Other, net
0 JPY
5,000,000 JPY
Net cash provided by (used in) investing activities
-5,000,000 JPY
1,166,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
500,000,000 JPY
Repayments of long-term borrowings
-1,206,000,000 JPY
-1,053,000,000 JPY
Purchase of treasury shares
0 JPY
0 JPY
Dividends paid
-1,000,000 JPY
-1,000,000 JPY
Other, net
-4,000,000 JPY
-4,000,000 JPY
Net cash provided by (used in) financing activities
-1,181,000,000 JPY
1,539,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
112,000,000 JPY
49,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-712,000,000 JPY
2,447,000,000 JPY
Cash and cash equivalents
4,532,000,000 JPY
5,244,000,000 JPY
2,797,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.